Stories

Targeting what cannot be seen: Lindsey Rodrigues on the complexity of epigenetics or mutated in a particular cancer. We have to ask, ‘do we have an understanding of how this gene works? Can we design a medicine to treat it or to target it?”’

We’re proud to be part of The Liver Meeting 2025 hosted by the American Association for the Study of Liver Disease (AASLD), where leading healthcare professionals, scientists and the patient community come together to discuss the latest advances in scientific and medical innovations and care, across

Liver disease has emerged as a critical focus for the healthcare science community, driven by significant unmet needs—particularly in rare and underserved conditions.

The first six months of 2025 have been exceptional for Ipsen. We’ve delivered strong growth across all three of our therapeutic areas — Rare Disease, Oncology, and Neuroscience — reflecting the strength of our strategy and the dedication of our teams. 

Every person’s experience living with neuroendocrine tumors (NETs) is unique and for Melanie, coming to terms with a diagnosis of lung NETs is an ongoing journey, building knowledge and understanding of how to live with this complex and often unknown form of cancer.